Delving into the Latest Updates on LIT0922 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

LIT0922

Target

mTORC2

Action

inhibitors

Mechanism

mTORC2 inhibitors(mTOR Complex 2 inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Shanghai LiteDD Co., LtdStartup

Active Organization

Shanghai LiteDD Co., LtdStartup

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的： 1.评估 LIT0922 胶囊的安全性和耐受性； 2. 通过评估 LIT0922 胶囊在晚期实体瘤患者中的剂量限制性毒性（DLTs），确定最大耐受剂量（MTD）；3. 确定 RP2D 次要目的： 1.评估 LIT0922 胶囊的药代动力学（PK）特征； 2.初步评估 LIT0922 胶囊的抗肿瘤活性； 3. 初步评估生物标记物与疗效之间的相关性

[Translation]

Primary objectives: 1. Evaluate the safety and tolerability of LIT0922 capsules; 2. Determine the maximum tolerated dose (MTD) by evaluating the dose-limiting toxicities (DLTs) of LIT0922 capsules in patients with advanced solid tumors; 3. Determine the RP2D Secondary objectives: 1. Evaluate the pharmacokinetic (PK) characteristics of LIT0922 capsules; 2. Preliminary evaluation of the anti-tumor activity of LIT0922 capsules; 3. Preliminary evaluation of the correlation between biomarkers and efficacy

Start Date-

Sponsor / Collaborator

Shanghai LiteDD Co., LtdStartup

100 Clinical Results associated with LIT0922

Login to view more data

100 Translational Medicine associated with LIT0922

Login to view more data

100 Patents (Medical) associated with LIT0922

Login to view more data

100 Deals associated with LIT0922

Login to view more data